Plasma lipidomics profiling in predicting the chemo-immunotherapy response in advanced non-small cell lung cancer.

ABSTRACT:

Background

Advanced non-small cell lung cancer (NSCLC) presents significant treatment challenges, with chemo-immunotherapy emerging as a promising approach. This study explores the potential of lipidomic biomarkers to predict responses to chemo-immunotherapy in advanced non-small cell lung cancer (NSCLC) patients.

Methods

A prospective analysis was conducted on 68 NSCLC patients undergoing chemo-immunotherapy, divided into disease control (DC) and progressive disease (PD) groups based on treatment response. Pre-treatment serum samples were subjected to lipidomic profiling using liquid chromatography-mass spectrometry (LC-MS). Key predictive lipids (biomarkers) were identified through projection to latent structures discriminant analysis. A biomarker combined model and a clin

SUBMITTER: Jiang H 

PROVIDER: S-EPMC11260645 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature